Genfit (NASDAQ:GNFT) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genfit (NASDAQ:GNFT) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

Genfit Stock Up 15.5 %

Genfit stock opened at $4.84 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.94 and a quick ratio of 2.94. Genfit has a 12-month low of $2.89 and a 12-month high of $6.05. The firm has a 50 day moving average of $4.23 and a 200 day moving average of $4.06.

Institutional Trading of Genfit

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its position in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,359 shares of the company’s stock after buying an additional 78,823 shares during the period. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.